DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Syon Capital LLC

Syon Capital LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 9.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,549 shares of the medical device company’s stock after buying an additional 401 shares during the period. Syon Capital LLC’s holdings in DexCom were worth $564,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Sands Capital Management LLC lifted its holdings in shares of DexCom by 4.3% in the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock worth $1,274,541,000 after acquiring an additional 557,543 shares during the last quarter. Blair William & Co. IL lifted its stake in DexCom by 1.7% during the third quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after purchasing an additional 73,654 shares in the last quarter. Northern Trust Corp boosted its position in shares of DexCom by 2.4% during the third quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock worth $363,545,000 after buying an additional 91,249 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of DexCom by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock valued at $201,618,000 after buying an additional 28,621 shares in the last quarter. Finally, Winslow Capital Management LLC purchased a new stake in shares of DexCom in the 3rd quarter valued at $173,120,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Canaccord Genuity Group boosted their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Finally, Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.67.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last quarter. Company insiders own 0.41% of the company’s stock.

DexCom Price Performance

DXCM opened at $124.34 on Friday. The company has a market capitalization of $49.24 billion, a P/E ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. The company has a 50-day moving average of $131.13 and a 200-day moving average of $118.30. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.38% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. Equities analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.